Anping Zheng

机构：Henan University of Science and Technology, Anyang Tumor Hospital

发表论文 5 篇 · 总被引 59 次 · h-index 3

代表论文

• Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial (2023 · British Journal of Cancer · 被引 23)
• Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial (2024 · Journal of Clinical Oncology · 被引 17)
• Deep Learning for Automated Contouring of Gross Tumor Volumes in Esophageal Cancer (2022 · Frontiers in Oncology · 被引 16)
• Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial (NXCEL1311 Study). (2022 · Journal of Clinical Oncology · 被引 3)
• Camrelizumab combined with concurrent chemoradiotherapy for locally recurrent esophageal cancer: A single-arm, open-label study. (2025 · Journal of Clinical Oncology)